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Abstract
As a result of mammographic detection, ductal carcinoma in situ (DCIS) is an increasing problem in breast clinics. Both histo-
pathology and molecular profiling can identify subtypes likely to progress to invasive disease, but there is no subgroup with a
zero likelihood of subsequent invasion. In patients with low/intermediate grade DCIS, if breast irradiation is not being carried
out after free margins have been achieved the patient should be aware of the risks of withholding and the benefits and morbid-
ity of adjuvant radiotherapy. Either tamoxifen or an aromatase inhibitor may be of value in those with low/intermediate ER+ve
disease if radiotherapy is being withheld. For those patients with extensive or multicentric DCIS, mastectomy is the appropriate
treatment. This is best combined with sentinel node biopsy and all such cases should be offered immediate reconstruction.
Keywords:Ductal carcinoma in situ; High grade; Low/intermediate grade; Recurrence; Progression; Radiotherapy; Tamoxifen;
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Introduction
In the not so distant past, no real distinction was made be-
tween invasive breast cancer and ductal carcinoma in situ
(DCIS), both being treated by mastectomy, often including an
axillary clearance. Such radical surgery for DCIS became
questioned as results emerged from randomised trials indi-
cating that breast conservation was a safe and effective al-
ternative to mastectomy for invasive breast cancer.1, 2, 3, 4, 5 At
the same time, as a by-product of national mammographic
screening programmes, the incidence of DCIS was increasing,
representing up to a quarter of screen-detected malignancy.
In the US in 1975 the incidence of DCIS was 2 per 100,000
and by 1985 was 10, rising to 22 in 1995 and 30 by 2005.6
Was it reasonable to offer a mastectomy for a non-life
threatening condition? We know now that the answer is “yes
and no”. For some women, as a result of incomplete excision
of DCIS, progression to invasive disease will reduce life ex-
pectancy. But are we yet in a position to individualise treat-
ment for women diagnosed with DCIS? The aim of treatment
is to eradicate the DCIS thereby reducing the risk of recur-
rence of DCIS or progression to invasive disease. DCIS is a
miscellany of conditions with a spectrum of risk of malig-
nancy and it is essential that it is not universally downgraded
to being regarded as a benign precursor of with an attendant
laissez faire attitude towards the management of high grade
disease.
Histopathology
Randomised trials of treatment for DCIS have not only
yielded evidence of relative efficacy of treatments tested but
have also led to central pathological review by pathologists
with a special interest in breast cancer. This has enabled the
delineation of groups with differing risks of subsequent re-
lapse or progression to invasive disease.
Pinder et al conducted a full pathological review of 1222/1694
(72 %) of specimens from women participating in the
UKCCCR/ANZ DCIS trial.7 Those pathological features asso-
ciated with ipsilateral recurrence in univariate analysis in-
cluded high cytonuclear grade, larger lesions, growth pattern,
presence of necrosis or chronic inflammation, margin in-
volvement or uncertainty of margin status and narrower
margin width. The large group of high-grade lesions was
subdivided to identify a very poor prognosis subgroup; DCIS
of high cytonuclear grade, with >50 % solid architecture,
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comedo-type necrosis in >50% of ducts. After a median fol-
low-up of 53 months, hazard ratios for ipsilateral in situ or
invasive recurrence in low, intermediate, high and very high,
grade were 0.42, 0.33, 0.62 and 1.00, respectively.
Because they found little difference in ipsilateral recurrence
rates between low- and intermediate-grade groups they
joined these two to form a 3 tier system: low/intermediate,
high and very high. Results are shown in TABLE 1. Although
the new categorisation does identify groups with different
risks of DCIS relapse and progression to invasive disease,
there is no group with a zero probability of invasive progres-
sion.






Low/intermediate 311 11 (3.5%) 8 (2.5%)
High 430 32 (7.4%) 14 (3.3%)
Very high 483 56 (11.6%) 32 (6.6%)
In the histopathological review of EORTC trial 10853,
specimens from 863/1010 (85%) were examined and a mul-
tivariate analysis was conducted of clinicopathological fea-
tures and relapse risk after a median follow-up of 5.4 years.8
Significant variables to emerge from multivariate analysis
included young age ≤ 40 years (hazard ratio 2.14), sympto-
matic DCIS (HR 1.8) solid and comedo growth pattern (HR
2.6 and 2.69), margin involvement (HR 2.07) and excision
without radiotherapy (HR 1.7). It is noteworthy that margin
status was a more major risk factor for recurrence than
avoidance of breast irradiation.
It could be argued that what is important in treatment of
DCIS is the avoidance of invasive relapse rather than recur-
rence of DCIS since this is not life threatening. The situation
is however more complex. In EORTC 10853 there was no
significant relationship between the type of DCIS and risk of
progression to invasion. When however the risk of distant
metastasis of invasive cancer was examined it was signifi-
cantly elevated in those with high grade DCIS (HR 6.57).
Esserman et al have suggested the acronym IDLE (indolent
lesions of epithelial origin) to encompass abnormalities which
may not be precursors of invasive cancer, such as low grade
DCIS.9 This is good insofar as some patients will be saved from
unnecessarily radical surgery but will be problematic if im-
perfectly characterised lesions are included, thereby placing
them at increased risk of invasive disease.
Molecular profiling
Clark et al constructed tissue microarrays (TMA) for 188 cases
of DCIS and examined expression patterns of estrogen re-
ceptor (ER), progesterone receptor (PR), HER2, EGFR, cy-
tokeratin (CK) 5/6, CK14, CK17, CK18, b4-integrin,
b6-integrin, p53, SMA, maspin, Bcl-2, topoisomerase IIa and
P-cadherin. Hierarchical clustering analysis was undertaken
to identify any natural groupings, and the findings were
validated in an independent series of 75 cases. Although the
intrinsic molecular subtypes could be identified in DCIS,
subgroup frequency varied. In DCIS the triple negative and
basal-like phenotype was very uncommon.  Hierarchical
cluster analysis identified three main subtypes of DCIS and
the 4 main markers were ER, PR, Her2 and Bcl-2, related to
conventional prognostic indicators. These subtypes
ER-PR-BCL-HER2+, ER-PR-BCL-HER2-, R+PR+HER2-BCL-
and ER+PR+HER2-BCL+ were confirmed in the validation
series of DCIS cases.
Solin et al examined specimens from 327 women with pure
DCIS who participated in Eastern Cooperative Oncology
Group (ECOG) E5194 study.10 Those with low or intermedi-
ate grade DCIS were observed without having breast irradia-
tion and some took tamoxifen. Oncotype DX breast cancer
assay was performed to obtain a prospectively defined DCIS
Score (based on 7 cancer-related genes (Ki67, STK15, Sur-
vivin, CCNB1 (cyclin B1), MYBL2, PR, GSTM1 and 5 refer-
ence genes). The continuous DCIS Score was statistically
significantly associated with the risk of developing an ipsi-
lateral breast event (IBE). For the of low, intermediate, and
high DCIS risk groups the 10-year risks of developing an
invasive IBE, were 3.7%,12.3%, and 19.2%, respectively ( P ≤
.006). In multivariable analyses, factors significantly associ-
ated with IBE risk were DCIS Score, tumour size, and
menopausal status.
Need for breast irradiation
The four major trials of treatment for DCIS had the main aim
of determining whether radiotherapy was a necessary part of
the treatment after excision of DCIS.11, 12, 13, 14 All have shown
the impact of breast irradiation on DCIS relapse and invasive
progression. As an example, in EORTC 10853, the 10-year
local relapse-free (LR) rate was 74 % in the group treated
with local excision (LE) alone compared with 85% in those
treated by LE plus RT (log-rank P <.0001; hazard ratio [HR] =
0.53). The risks of DCIS relapse and invasive progression were
reduced by 48 % (P <.0011) and 42 % (P < 0065) respectively.
The effect of RT was homogeneous across all assessed risk
factors, that is, there was no subgroup in which it could be
shown that radiotherapy was redundant.15 Despite this series
with long term follow-up are published in which women
with completely excised low and intermediate DCIS, <2cm
are treated by wide excision and no radiotherapy. In a recent
publication, Wehner et al reported 205 women treated with
LE alone among whom the 6 years probability of relapse was
6.6%16, similar to that in the low/intermediate category in the
UKCCCR/ANZ DCIS trial.
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Adjuvant tamoxifen
Tamoxifen has been tested in two prospective randomised
trials, NSABP B 2417 and UKCCCR/ANZ DCIS.18 In B24, 1804
women with DCIS, including those with margin involve-
ment, were treated by lumpectomy, radiotherapy, and ta-
moxifen 20 mg daily for 5 years or lumpectomy, radiation
therapy, and placebo. To be eligible for UKCCCR/ANZ DCIS,
the 1701 participants had complete local excision of DCIS and
were randomised in a 2x2 factorial manner to observation,
radiotherapy, tamoxifen or radiotherapy and tamoxifen.
Long-term results are shown in TABLE 2.
In B24, after a median follow-up of 163 months, the overall
ipsilateral breast recurrence rate was 19% in the placebo arm
and 9% in the tamoxifen group.19 There was a reduction in
both DCIS relapse and invasive progression in the tamoxifen
arm. Allred et al determined estrogen (ER) and progesterone
receptors (PgR) in 732 (41%) of B24 participants.20 ER was
positive in 76% of patients. Those with ER-positive DCIS who
received tamoxifen had significant reduction in subsequent
breast cancer at 10 years (hazard ratio [HR], 0.49; P < 0.001).
No significant effect was seen in ER-negative DCIS.
In UK/ANZ after 12.7 years median follow-up, tamoxifen
reduced both ipsilateral DCIS relapse and contralateral events
but had no impact on ipsilateral invasive progression.21 The
non-concordant results from the two trials may be a reflec-
tion of age differences. In the UK/ANZ trial where most cases
were derived from the screening programme >90% were aged
50 years or older.  In B24 however, most participants were
younger with only 34% being aged >50.
Staley et al conducted a Cochrane review of post-operative
tamoxifen for DCIS based on these 2 trials, totalling 3375
women.22 They concluded that tamoxifen reduced incidence
of both ipsilateral and contralateral DCIS (RR 0.50). There
was a non-significant trend towards more endometrial cancer
in the tamoxifen group but no impact on overall mortality.
Adjuvant aromatase inhibitors
No results are yet available from randomised trials such as
IBIS-2 on the effect of aromatase inhibitors in
post-menopausal women with ER positive DCIS.23 Dixon et al
reported that in a randomised neoadjuvant study of 206
postmenopausal women with invasive ER+ve breast 28 pre
and post-treatment specimens contained ER+ve DCIS.24 Both
anastrozole and letrozole significantly inhibited proliferation.
There was reasonable agreement between the fall in prolif-
eration within both the invasive and in situ components.
Chen et al conducted a neoadjuvant trial in which 9 patients
with ER-positive pure DCIS diagnosed by stereotactic core
biopsy were treated with letrozole, followed by excision
biopsy.25 Proliferation and apoptotic markers were measured
at baseline and at three months and compared with specimens
from patients not given preoperative treatment. There was
significant reduction of PR, and Ki67 as well as increase in
CD68-positive cells. The authors questioned whether those
responding might be able to avoid surgical intervention.
Magnetic resonance imaging (MRI)
MRI has been used particularly in women with dense breasts
in an attempt to determine the extent of DCIS, in the hope
that a one-stage operation can be performed. This may not
always be helpful. Davis et al reviewed 218 patients with
DCIS. Of whom 64 did not have a preoperative MRI, and154
who did.26 Re-excision rates were similar (34% and 39 %
respectively). Conversion rates to mastectomy were 9% and 8
%. Average specimen weights at definitive surgery were 50g
and 49g respectively. The authors concluded that preopera-
tive MRI did not add benefit to the care of women with DCIS.
A group from the Academic Medical Center Amsterdam
evaluated preoperative MRI to try and identify those patients
with DCIS who are at high risk of invasive breast cancer.27
There were 125 with pure DCIS on core biopsy and 18 (14 %)
had invasion on final histology. Suspicious enhancement on
MRI was seen in 73 lesions, with a type 1 curve was seen
in 12, type 2 in 19, and type 3 curve in 42. The most predic-
tive features on multivariate analysis for excluding invasive
disease were no enhancement or a type 1 curve and this had a
negative predictive value 98.5 %.
Pilewskie et al reviewed 352 patients with DCIS of whom 217
received MRI and 135 did not.28 There was no difference in
terms of type of initial surgery and number of reoperations
between the two groups. Successful breast conservation oc-
curred more frequently in the no-MRI group. Additional
biopsies were performed on 38 % of the MRI group compared
with 7 % in the no-MRI group; ≥2 additional biopsies were
performed in 18 % of the MRI group and 2 % of the no-MRI
group (p < 0.0001). These yielded a cancer diagnosis in 26 %
of MRI and 33 % of no-MRI patients. MRI was not as good as
mammography in detecting size of DCIS lesions preopera-
tively 52 % of mammograms were accurate within 10mm in
52 % of cases compared with 41 % of MRIs.
These data suggest that MRI is likely to pick up suspicious
looking lesions which are histologically non-malignant and
also does not, in most cases, add precision to determination of
extent of DCIS. Hence MRI should not be used in a screening
role when DCIS has been diagnosed but be reserved for those
cases where there is genuine difficulty in identifying multi-
centric or more extensive disease.
International Journal of Cancer Therapy and Oncology
www.ijcto.org
Copyright © Fentiman ISSN 2330-4049
TABLE 2: Breast events in NSABP B24 and UK/ANZ DCIS trials.
Feature NSABP 24 UK/ANZ DCIS
Treatment Placebo Tam Obs Tam RT Tam+RT
Number 900 899 544 567 267 376
Ipsilateral DCIS 68(7.5%) 60 (6.7%) 96 (18%) 72 (13%) 16 (6%) 13 (4%)
Ipsilateral INV 81 (9%) 59 (6.5%) 52 (10%) 49 (9%) 10 (4%) 11 (3%)
Contralateral DCIS 25 (3%) 14 (1.5%) 9 (2%) 4 (1%) 2 (1%) 2 (1%)
Contralateral INV 48 (5%) 30 (3%) 20 (4%) 7 (1%) 5 (2%) 7 (2%)
Abbreviations: Tam = tamoxifen; Obs = Observation; RT = Radio therapy
Surgery
Although a small proportion of patients with DCIS present
with symptomatic disease, a lump or nipple discharge, the
majority of cases will be picked up following mammography.
When micro calcification graded as M3, M4 or M5 is ob-
served an ultrasound will be carried out to determine
whether there is an associated mass and also to examine
whether abnormal axillary nodes are present. In the absence
of a mass, a stereotactic core is performed and a marker in-
serted at the site of the core biopsies. This obviates need for a
subsequent stereotactic core since the marker acts as a target
for an ultrasound guided wire localisation. In some cases the
DCIS will be clearly identified and extent can be measured. If
there is extensive micro calcification, by taking cores from
close to the margins may be useful so that there is histological
proof of extent. This may help to persuade the patient to
undergo mastectomy rather than breast conserving surgery.
Localised wide excision
The standard method of dealing with an impalpable breast
lesion was wire localisation under ultrasound or stereotactic
guidance, followed by surgical excision under general an-
aesthesia.29 Kohler et al evaluated ultrasound and mammog-
raphy guided wire marking in 668 women with 741 impal-
pable breast lesions. Ultrasound was used in 418, mammog-
raphy in 284 and for 39 lesions both techniques were com-
bined. Specimen ultrasound suggested that 91 % of lesions
were resected completely and specimen x-ray suggested
complete resection in 89%. Histologically 20 % of the ma-
lignant lesions marked with sonography and 37 % of cancers
marked mammographically had involved margins.
Re-excision was necessary in 10 patients localised by ultra-
sound and in 25 patients who were x-ray localised.
Wire guided localisation (WGL) was usually successful but
could be painful for the patient and occasionally the marker
moved due to traction on the wire. To avoid this, in 1999,
Luini et al. reported a new technique using a small quantity of
99mTc-labelled colloidal albumin is injected directly into the
lesion under stereotactic-radiographic or ultrasonic guid-
ance.30 A gamma probe was then used to locate the lesion and
guide the surgical excision. The results of radio-guided occult
lesion localisation (ROLL) in 30 patients were compared with
wire localisation in another 30 patients. In the WGL group,
the mean distance from the lesion centre to the specimen
margin was 25mm compared with 14mm in the radio-guided
group so that ROLL removal reduced excision volume.
Several relatively small trials suggested that ROLL and WGL
were equivalent.31, 32, 33 Van der Ploeg et al. reviewed the
available literature and concluded that ROLL was a promising
technique, which achieved complete excision more fre-
quently than WGL and was more accurate and faster.34 Sub-
sequently, contrary evidence came from a multicentre ran-
domised controlled trial comparing ROLL and WGL for
preoperative tumour localisation.35 Complete tumour re-
moval was achieved in 140/162 (86 %) patients in the ROLL
group and 134/152 (88 %) patients in the WGL group.
Re-excision was required in 12 % of the ROLL group versus
10 % in the WGL group. Mean specimen volumes were 71cm3
versus 64cm3 in the ROLL and WGL arms respectively. No
significant differences were observed in the duration and
difficulty of either the radiological or surgical procedures. It
was suggested that ROLL cannot replace WGL as the standard
of care.
Arentz et al hypothesized that the hematoma-directed ul-
trasound-guided (HUG) procedure to localise impalpable
lesions would allow excision without the problems of WGL
and decrease the high rate of margin positivity.36 A multi-
frequency linear array transducer was employed intraopera-
tively for the HUG localisation, and a block of tissue sur-
rounding the hematoma removed.  Results were reported in
455 patients of whom 126 (28 %) had needle localization and
329 (72 %) underwent HUG. The previous core-biopsy site
was successfully excised in all patients using HUG. Of those
with cancer margins were positive in 24 % of HUG compared
with 47 % of those needle localised. This suggests that HUG is
more accurate in localising impalpable lesions than WGL but
the technique is dependent upon the surgeon being trained in
this aspect of ultrasound.
Margins
Although there is agreement that the aim is to achieve un-
involved margins, there has been disagreement concerning
margin width. Dunne et al carried out a review of published
trials examining outcomes after breast conserving surgery and
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radiotherapy for DCIS.37 There were 4,660 patients and those
with negative margins were at substantially reduced risk of
relapse compared with those with positive margins (Odds
ratio 0.36). Negative margins were better than close margins
in terms of relapse (OR 0.59). A 2mm margin was better than
<2 mm (OR 0.53). There was however no significant differ-
ence in relapse rate with margins 2-5 mm or >5mm.
Wang et al criticised the methodology used by Dunne, argu-
ing that only randomised trials were included and here was
duplication of data with multiple studies from the same in-
stitution drawing on overlapping patient sources.38 Addi-
tionally, Dunne pooled study results and did not use them as a
stratification factor. Wang et al identified 21 randomised and
non-randomised studies with a total of 7564 women and
performed a network meta-analysis. Of the patients, 3098
were treated by BCS alone and 4466 with additional radio-
therapy. Ipsilateral relapse occurred in 565 (16 %) and 501 (11
%) respectively.
Comparing negative with positive margins, there was a re-
duced relapse risk both with radiotherapy (OR = 0.46), and
without radiotherapy (OR = 0.34). For positive margins versus
negative margin >0 mm, >2, >5 and ≥10 mm the ORs were
0.45, 0.38, 0.55, and 0.17 respectively. When comparing a
negative margin >2 mm, with a negative margin of ≥10 mm
the latter carried a lower risk of relapse (OR = 0.46). They
concluded that within the constraints of satisfactory cosmesis,
an attempt should be made to achieve wide negative margins
but that further studies should determine whether margin
thresholds >10 mm are of benefit.
Sentinel node biopsy
Ansari et al conducted a meta-analysis of results from 22
series of sentinel biopsy (SNB) in 3166 patients with a
pre-operative diagnosis of DCIS.39 The average rate of sentinel
node involvement was approximately 7%. When however
the post-operative diagnosis was DCIS alone the rate of nodal
positivity fell to 4%. Studies predicting invasive disease after a
core biopsy showing DCIS have shown that the significant
variables were high grade DCIS, >2.5cm, <12 core biopsies,
palpable mass, mass on imaging and inflammatory infiltrate
in the core biopsy.
Osako et al investigated SNB in a large cohort of women
with DCIS. The node was subjected to frozen section (FS)
analysis in 338 patients treated between 2007 and 2009. For
285 who undergoing surgery between 2009 and 2011 the
sentinel node (SN) was examined using the one-step nucleic
acid amplification (OSNA) assay. More cases of SN metastases
were detected by OSNA than FS (12/285 (4 % versus 1/338
(0.3 %). The majority were micrometastases. The character-
istics of DCIS at high-risk of invasion (mass, size, grade, and
comedo type, preoperative breast biopsy) did not apply to
OSNA assay–positive DCIS.
For those patients having immediate reconstruction it is best
that the SNB is carried out as a stand-alone procedure in
order that the axillary nodal status in known before em-
barking on what may be a complex reconstruction. If this has
not been carried out the need to carry out carry out a com-
pletion axillary clearance may compromise the achievement
of a good cosmetic result.
Which patients with DCIS require a mastectomy?
There is probably less argument about indications for mas-
tectomy in women with DCIS than there is concerning suit-
ability for breast conserving surgery. An absolute indication is
histologically proven presence of DCIS in more than one
quadrant. In the event of multifocal rather than multicentric
disease, the main consideration is whether the DCIS can be
extirpated and still leaves the patient with a reasonable cos-
metic result. Trials have varied in maximum allowable extent
of DCIS but the clinical decision should be based on the ex-
tent of disease in relation to the size of the breast.
When the extent of DCIS mandates mastectomy a sentinel
node biopsy should be performed. Upstaging from DCIS to
invasive disease occurs in up to 20% of cases with pure DCIS
on the original core.40, 41 When invasive disease is present it is
now accepted that; provided axillary ultrasound is normal,
sentinel node biopsy is the best method of staging the axilla.42
Ansari et al reported a meta-analysis of results from 22 series
of sentinel biopsy in 3166 patients with a pre-operative di-
agnosis of DCIS.43 The average rate of sentinel node in-
volvement was approximately 7 %. When however the
post-operative diagnosis was DCIS alone the rate of nodal
positivity fell to 3.7 %.
The greater the extent of DCIS the higher the risk of associ-
ated invasion. In a series of 398 women with pure DCIS on
core biopsy operated on at the MD Anderson Hospital 20 %
were upgraded on final histology.44 Multivariate analysis
indicated that the significant prognostic variables included
younger age, high grade DCIS and mammographic size ≥4cm.
The same group reported later that invasive carcinoma was
found at definitive surgery in 30 % of those with DCIS
>15mm and only 11 % of those with DCIS ≤15mm.45
It is often assumed that a total mastectomy provides a cure for
DCIS, with a zero risk of local recurrence. Unfortunately this
is not true. Residual breast tissue may be left behind, par-
ticularly in the axillary tail and in the most inferior part of the
breast. The larger series that have reported recurrence rates
after mastectomy for ductal carcinoma. In situ are summa-
rised in Table 3.46, 47, 48, 49 This indicates that 1-2 % of patients
will develop a relapse. Kelley et al used the USC Van Nuys
Prognostic Index, which is an algorithm based on DCIS size,
nuclear grade, necrosis, margin width, and patient age. Re-
currence occurred in 11 patients, all of whom scored 10–12
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using the USC/VNPI and all had multifocal disease and co-
medo-type necrosis.
TABLE 3: Recurrence after mastectomy for DCIS.
Author N Recurrence Follow-up
Bedwani 198146 112 1(1%) 60 months
Silverstein 199547 228 2 (1%) 78 months
Van der Velden 200748 408 4 (1%) 65 months
Kelley 201149 496 11 (2%) 83 months
Management plan
An algorithm for management of DCIS is given in Figure 1.
Treatment should not be planned until there is histological
confirmation of the diagnosis of DCIS, accepting that up to 20
% of cases will eventually prove to have inva-
sion/microinvasion. Outside of research protocols breast MRI
should be confined to those cases where the extent of disease
is indeterminate. All patients undergoing mastectomy for
extensive DCIS should have a sentinel node biopsy as part of
primary treatment. Sentinel node biopsy should also be con-
sidered for patients with DCIS ≥2.5cm having a wide excision
because of the high risk of invasive disease being pre-
If a mastectomy is deemed necessary this will normally be a
skin sparing procedure since this has been shown to be as
effective as a standard mastectomy in terms of local control of
disease and can help to achieve a better cosmetic outcome.50
The Gustave Roussy Breast Cancer Study Group Data ana-
lysed 238 consecutive patients diagnosed with DCIS and who
had undergone mastectomy and SNB between 2005 and
2011.51 Of these, 57% had immediate breast reconstruction 43
% did not. The commonest reason for immediate reconstruc-
tion not being offered was that it had not been mentioned by
the surgeon (33.4 %). The rate of immediate reconstruction
was highest in those <50 and (52.2 %), and was lower among
women with diabetes (0.7 %) or obesity (8.8 %). The choice of
reconstruction was unaffected by tobacco use or positive
lymph node status. This report from a centre of excellence
highlights a potential lacuna in communication. Discussion of
immediate reconstruction should be an intrinsic part of dis-
cussion between the surgeon and the patient with DCIS.
In a small series of 14 nipple-saving mastectomies (NSM),
Nahabedian and Tsangaris reported that sensation was pre-
sent in 43 %, delayed healing occurred in 29 % and symmetry
was achieved in five of 50%.52 Local relapse occurred 27%,
and secondary procedures were required in 36%. Reviewing
the evidence for efficacy and safety of nipple-preserving
mastectomy in 2006, Garcia-Etienne and Borgen concluded
that the published studies lacked the power to determine a
role for NSM.53
FIG. 1: Algorithms for DCIS management.
The situation changed when Petit et al reported a series of
570 patients with breast cancer treated by NSM were per-
formed for carcinoma.54 An immediate frozen section was
taken from retroareolar tissue. If tumour was present the
patient was not treated by NSM (63/570, 12%). Likelihood of
areola positive histology increased with tumour size but was
unrelated to the nodal status. The local recurrence rate was
0.9% per year. Provided that appropriate control is observed
and in experienced hands, NPM is a safe surgical option in
selected patients with DCIS.
Conflict of interest
The authors declare that they have no conflicts of interest.
The authors alone are responsible for the content and writ-
ing of the paper.
References
1. Veronesi U, Saccozzi R, Del Vecchio M, et al.
Comparing radical mastectomy with
quadrantectomy, axillary dissection, and radio-
therapy in patients with small cancers of the breast.
N Engl J Med 1981; 305: 6-11.
2. Fisher B, Redmond C, Poisson R, et al. Eight-year
results of a randomized clinical trial comparing to-
tal mastectomy and lumpectomy with or without
sent.39
Volume 1 • Number 2 • 2013                                            International Journal of Cancer Therapy and Oncology 7
www.ijcto.org
Copyright © Fentiman ISSN 2330-4049
irradiation in the treatment of breast cancer. N
Engl J Med 1989; 320: 822-8.
3. Van Dongen JA, Bartelink H, Fentiman IS, et al.
Factors influencing local relapse and survival and
results of salvage treatment after breast-conserving
therapy in operable breast cancer: EORTC Trial
10801, breast conservation compared with mastec-
tomy in TNM stage I and II breast cancer. Eur J
Cancer 1992; 28A: 801-5.
4. Jacobson JA, Danforth DN, Cowan KH, et al.
Ten-year results of a comparison of conservation
with mastectomy in the treatment of stage I and II
breast cancer. N Engl J Med 1995; 332: 907-11.
5. van Dongen JA, Bartelink H, Fentiman IS, Peterse
6. Virnig BA, Tuttle TM, Shamliyan T, Kane RL.
Ductal carcinoma in situ of the breast: a systematic
review of incidence, treatment, and outcomes. J
Natl Cancer Inst 2010; 102:170–178.
7. Pinder SE, Duggan C, Ellis IO, Cuzick J, Forbes JF,
Bishop H, Fentiman IS & George WD. A new
pathological system for grading DCIS with im-
proved prediction of local recurrence: results from
the UKCCCR/ANZ DCIS trial. Br J Cancer 2010;
103: 94-100.
8. Bijker N, Petersee JL, Duchateau L, Julien J-P,
Fentiman IS, et al. Risk factors for recurrence and
metastasis after breast conserving therapy for duc-
tal carcinoma in situ: analysis of European Organi-
sation for Research and Treatment of cancer trial
10853. J Clin Oncol 2001; 19: 2263-2271.
9. Esserman L, Shieh Y, Thompson I. Rethinking
screening for breast cancer and prostate cancer.
JAMA 2009; 302:1685-1692.
10. Solin LJ, Gray R, Baehner FL, Butler SM, Hughes
LL, et al. A multigene expression assay to predict
local recurrence risk for ductal carcinoma in situ of
the breast. J Natl Cancer Inst 2013; 105:701–710.
11. Wapnir IL, Dignam JJ, Fisher B, Mamounas EP,
Stewart J. Anderson SJ, et al. Long-term outcomes
of invasive ipsilateral breast tumor recurrences af-
ter lumpectomy in NSABP B-17 and B-24 random-
ized clinical trials for DCIS. J Natl Cancer Inst
2011; 103: 478–488.
12. Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S,
Bundred NJ, Forbes JF, Bishop H, Fentiman IS,
George WD. Effect of tamoxifen and radiotherapy
in women with locally excised ductal carcinoma in
situ: long-term results from the UK/ANZ DCIS tri-
al. Lancet Oncol 2011; 12: 21-29.
13. Donker M, Litiere S, Werutsky G, Julien JP,
Fentiman IS, et al. Breast-conserving treatment
with or without radiotherapy in Ductal Carcinoma
In Situ: 15-year Recurrence Rates and Outcome
After a Recurrence, from the EORTC 10853 Ran-
domized Phase III Trial. Journal of Clinical Oncol-
ogy 2013; 31:4054-4059.
14. Holmberg L, Garmo H, Granstrand B, et al. Abso-
lute risk reductions for local recurrence after post-
operative radiotherapy after sector resection for
ductal carcinoma in situ of the breast. J Clin Oncol
2008; 26:1247–1252.
 Cancer Inst 
with excision alone using the national Comprehen-
sive Cancer Network (NCCN) Guidelines. Ann
Surg Oncol 2013; 20: 3175-9.
17. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen
in treatment of intraductal breast cancer: National
Surgical Adjuvant Breast and Bowel Project B-24
randomised controlled trial. Lancet 1999; 353:
1993–2000.
18. Houghton J, George WD, Cuzick J, Duggan C,
Fentiman IS, Spittle M; UK Coordinating Commit-
tee on Cancer Research; Ductal Carcinoma in situ
Working Party; DCIS trialists in the UK, Australia,
and New Zealand. Radiotherapy and tamoxifen in
women with completely excised ductal carcinoma
in situ of the breast in the UK, Australia, and New
Zealand: randomised controlled trial. Lancet 2003;
362:95-102.
19. Wapnir IL, Dignam JJ, Fisher B, et al. Long-term
outcomes of invasive ipsilateral breast tumor re-
currences after lumpectomy in NSABP B-17 and
B-24 randomized clinical trials for DCIS. J Natl
Cancer Inst 2011; 103:478–488.
20. Allred DC, Anderson SJ, Paik S, et al. Adjuvant
tamoxifen reduces subsequent breast cancer in
women with estrogen receptor–positive ductal car-
cinoma in situ: a study based on NSABP Protocol
B-24. J Clin Oncol 2012; 30:1268-1273.
21. Cuzick J, Sestak I, Pinder SE, et al. Effect of
tamoxifen and radiotherapy in women with locally
excised ductal carcinoma in situ: long-term results
from the UK/ANZ DCIS trial. Lancet Oncol 2011;
12: 21-9.
22. StaleyH, McCallum I, Bruce J. Postoperative
tamoxifen for ductal carcinoma in situ. Cochrane
Database Syst Rev 2012; 10:CD007847.
23. Cuzick J. Aromatase inhibitors in prevention – data
from the ATAC (Arimidex, tamoxifen alone or in
combination) trial and the design of IBIS-II (the
second International Breast Cancer Intervention
Study). Recent Results Cancer Res 2003;
163:96–103.
24. Dixon JM, Faratian D, White S et al. DCIS and
aromatase inhibitors. J Steroid Biochem Mol Biol
2007; 106:173-9.
JL. Ductal carcinoma in situ (DCIS) of the breast –a
therapeutic dilemma. Eur J Surg Oncol 1987; 13:
123-126.
Monogr 2010; 2010:162–177.
16. Wehner P, Lagios MD, Silverstein MJ. DCIS treated
15. Correa  C,  McGale  P,  Taylor  C,  et  al. Early  
Breast Cancer Trialists’ Collaborative Group .  J     
 Natl              
8 Fentiman : Getting the right balance in treatment of DCIS International Journal of Cancer Therapy and Oncology
www.ijcto.org
Copyright © Fentiman ISSN 2330-4049
25. Chen YY, DeVries S, Anderson J, Lessing J, et al.
Pathologic and biologic response to preoperative
endocrine therapy in patients with ER-positive
ductal carcinoma in situ. BMC Cancer 2009; 9:285.
26. Davis KL, Barth RJ Jr, Gui J, et al. Use of MRI in
preoperative planning for women with newly di-
agnosed DCIS: risk or benefit? Ann Surg Oncol
2012; 19:3270-4.
27. Deurloo EE, Sriram JD, Teertstra HJ, et al. MRI of
the breast in patients with DCIS to exclude the
presence of invasive disease. Eur Radiol 2012;
22:1504-11.
28. Pilewskie M, Kennedy C, Shappell C, et al. Effect
of MRI on the management of ductal carcinoma in
situ of the breast. Ann Surg Oncol 2013;
20:1522-9.
29. Chaudary MA, Reidy JF, Chaudhuri R, Millis RR,
Hayward JL, Fentiman IS. A new and improved
device for the pre-operative localisation of impal-
pable breast lesions. Br J Surgery 1990; 77:
1191-1192.
30. Luini A, Zurrida S, Paganelli G, et al. Comparison
of radioguided excision with wire localization of
occult breast lesions. Br J Surg 1999; 86:522-5.
31. Medina-Franco H, Abarca-Perez L, García-Alvarez
MN. Radioguided occult lesion localization (ROLL)
versus wire-guided lumpectomy for non-palpable
breast lesions: a randomized prospective evalua-
tion. J Surg Oncol 2008; 97:108-11.
32. Mariscal Martínez AM, Sola M, Perez de Tudela A.
Nonpalpable breast cancer lesions: randomized
comparison with wire localization in patients un-
dergoing conservative surgery and sentinel node
biopsy. AJR 2009; 193:1001–1009.
33. Sarlos D, Frey LD, Haueisen H, Landmann G, Kots
LA, Schaer G. Radioguided occult lesion localiza-
tion (ROLL) for treatment and diagnosis of malig-
nant and premalignant breast lesions combined
with sentinel node biopsy: a prospective clinical
trial with 100 patients. Eur J Surg Oncol 2009;
35:403-8.
34. van der Ploeg IM, Hobbelink M, van den Bosch
MA. Radioguided occult lesion localisation' (ROLL)
for non-palpable breast lesions: a review of the
relevant literature. Eur J Surg Oncol 2008; 34:1-5.
35. Postma EL, Verkooijen HM, van Esser S,
Hobbelink MG et al, Efficacy of 'radioguided occult
lesion localisation' (ROLL) versus 'wire-guided
localisation' (WGL) in breast conserving surgery
for non-palpable breast cancer: a randomised con-
trolled multicentre trial. Breast Cancer Res Treat
2012; 136:469-78.
36. Arentz C, Baxter K, Boneti C, et al. Ten-year expe-
rience with hematoma-directed ultrasound-guided
(HUG) breast lumpectomy. Ann Surg Oncol 2010;
17 Suppl 3:378-83.
37. Dunne C, Burke JP, Morrow M, Kell MR. Effect of
margin status on local recurrence after breast con-
servation and radiation therapy for ductal carcino-
ma in situ. J Clin Oncol 2009; 27:1615-1620.
38. Wang S-Y, Chu H, Shamliyan T, et al. Network
meta-analysis of margin threshold for women with
ductal carcinoma in situ. J Natl Cancer Inst 2012;
104:507–516.
39. Ansari B, Ogston SA, Purdie CA, et al. Me-
ta-analysis of sentinel node biopsy in ductal carci-
noma in situ of the breast. Br J Surg 2008; 95:
547-554.
40. Sakr R, Antoine M, Barranger E, et al. Value of
sentinel lymph node biopsy in breast ductal carci-
noma in situ upstaged to invasive carcinoma. Breast
J 2008; 14: 55-60.
41. Van la Parra RF, Ernst MF, Barneveld PC, et al.
The value of sentinel lymph node biopsy in breast
ductal carcinoma in situ (DCIS) and DCIS with
microinvasion of the breast. Eur J Surg Oncol 2008;
34: 631-5.
42. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida
S, Galimberti V et al. A randomized comparison of
sentinel-node biopsy with routine axillary dissec-
tion in breastcancer. N Engl JMed 2003; 349:
546–553.
43. Ansari B, Ogston SA, Purdie CA, et al. Me-
ta-analysis of sentinel node biopsy in ductal carci-
noma in situ of the breast. Br J Surg 2008; 95:
547-554.
44. Yen TWE, Hunt KK, Ross MI, et al. Predictors of
invasive breast cancer in patients with an initial
diagnosis of ductal carcinoma in situ: a guide to se-
lective use of sentinel lymph node biopsy in man-
agement of ductal carcinoma in situ. J Am Coll
Surg 2005; 200: 516-526.
45. Huo L, Sneige N, Hunt KK, et al. Predictors of in-
vasion in patients with core-needle biop-
sy-diagnosed ductal carcinoma in situ and recom-
mendations for a selective approach to sentinel
node biopsy in ductal carcinoma in situ. Cancer
2006; 107: 1760-8.
46. Bedwani R, Vana J, Rosner D, et al. Management
and survival of female patients with “minimal”
breast cancer. Cancer 1981; 47: 2769–2778.
47. Silverstein MJ, Barth A, Poller DN, et al. Ten-year
results comparing mastectomy to excision and ra-
diation therapy for ductal carcinoma in situ of the
breast. Eur J Cancer 1995; 31:1425–1427.
ion Oncology Biol Phys
2007; 69:703-10.
48. Schouten van der Velden AP, van Vugt R, Van
Dijck JA, et al. Local recurrences after different
treatment strategies for ductal carcinoma in situ of
the breast: a population-based study in the East
Netherlands. Int J Radiat
Volume 1 • Number 2 • 2013                                            International Journal of Cancer Therapy and Oncology 9
www.ijcto.org
Copyright © Fentiman ISSN 2330-4049
49. Kelley L, Silverstein M, Guerra L. Analyzing the
risk of recurrence after mastectomy for DCIS: a
new use for the USC/Van Nuys Prognostic Index.
Ann Surg Oncol 2011; 18:459–462.
50. Kroll SS, Schusterman MA, Tadjalli HE, Singletary
SE, Ames FC. Risk of recurrence after treatment of
early breast cancer with skin-sparing mastectomy.
Ann Surg Oncol 1997; 4:193-7.
51. Naoura I, Mazouni C, Ghanimeh J, Leymarie N, et
al. Factors influencing the decision to offer imme-
diate breast reconstruction after mastectomy for
ductal carcinoma in situ (DCIS): the Institut
Gustave Roussy Breast Cancer Study Group expe-
rience. Breast 2013; 22:673-5.
52. Nahabedian MY, Tsangaris TN Breast reconstruc-
tion following subcutaneous mastectomy for can-
cer: a critical appraisal of the nipple-areola com-
plex. Plast Reconstr Surg 2006; 117:1083-90.
53. Garcia-Etienne CA, Borgen PI. Update on the in-
dications for nipple-sparing mastectomy. J Support
Oncol 2006; 4:225-30.
54. Petit JY, Veronesi U, Rey P, et al. Nipple-sparing
mastectomy: risk of nipple-areolar recurrences in a
series of 579 cases. Breast Cancer Res Treat 2009;
114:97-101.
